Literature DB >> 25035320

Genome Sequences of the Oxytetracycline Production Strain Streptomyces rimosus R6-500 and Two Mutants with Chromosomal Rearrangements.

Damir Baranasic, Jurica Zucko1, Mridul Nair2, Arnab Pain2, Paul F Long, Daslav Hranueli1, John Cullum3, Antonio Starcevic4.   

Abstract

The genome sequence of Streptomyces rimosus R6-500, an industrially improved strain which produces high titers of the important antibiotic oxytetracycline, is reported, as well as the genome sequences of two derivatives arising due to the genetic instability of the strain.
Copyright © 2014 Baranasic et al.

Entities:  

Year:  2014        PMID: 25035320      PMCID: PMC4102857          DOI: 10.1128/genomeA.00517-14

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Streptomyces rimosus is used industrially for the production of the important antibiotic oxytetracycline, encoded by the otc cluster (1). Recently a draft genome sequence of the strain S. rimosus ATCC 10970 was published (2). Derivatives of the strain S. rimosus R6 were used by the company PLIVA to produce oxytetracycline and it was believed that they were derived from a soil isolate different from ATCC 10970 (1). The strain S. rimosus R6-500 is an improved industrial strain which produces significant quantities of oxytetracycline. It is genetically unstable and gives rise to derivatives such as MV9, which appear to have the otc cluster deleted (3). However, further analyses showed that the “deleted” sequences were present at low copy numbers (estimated at about 1/1,000 per chromosome copy) and gave rise to spontaneous revertants such as MV9-R8, in which some of the “deleted” sequences regained normal copy numbers (4). Genome sequences of the three S. rimosus strains R6-500, MV9, and MV9-R8 were obtained using the Illumina MiSeq sequencing platform. Paired-end reads of average single read length of 250 bp and a distance between pairs of ~400 bp were obtained. The assemblies were performed using the Velvet version 1.2.09 assembler (5) with 9 million R6-500 reads, 4 million MV9 reads, and 12 million MV9-R8 reads, using k-mers of length 51 to construct the hash tables. The assemblies yielded 243, 88, and 375 contigs, respectively, for R6-500, MV9, and MV9-R8, with N50 values of 284 kb, 179 kb, and 419 kb. The three genome sequences were annotated using the NCBI Prokaryotic Genome Annotation Pipeline (http://www.ncbi.nlm.nih.gov/genome/annotation_prok/) (6). R6-500 had 7,387 predicted protein coding genes. The S. rimosus R6-500 sequences showed >99% identity with the published ATCC 10970 sequences (2), indicating that R6-500 was derived from the ATCC 10970 soil isolate. However, ~600 kb of the ATCC 10970 sequences were not present in R6-500, so the strain improvement program had resulted in extensive deletions. Compared to R6-500, the mutant MV9 had deleted ~650 kb, including the otc cluster, whereas MV9-R8 had regained about 190 kb of the deleted sequence. In MV9 there were rare well-aligned reads to the deleted sequences, confirming their presence at low copy numbers in the strain. The genome sequence of S. rimosus R6-500 is interesting as it allows comparison of a high-producing industrial strain with the soil isolate ancestor represented by strain S. rimosus ATCC 10970 (2). Comparison with the strain MV9 and the revertant should throw light on this fascinating process, which allows Streptomyces strains to maintain large regions of the genome at low copy numbers (4).

Nucleotide sequence accession numbers.

These whole-genome shotgun projects have been deposited at DDBJ/EMBL/GenBank under the accession numbers JJNO00000000, JMGX00000000, and JMGY00000000. The versions described in this paper are versions JJNO01000000, JMGX01000000, and JMGY01000000.
  5 in total

1.  Velvet: algorithms for de novo short read assembly using de Bruijn graphs.

Authors:  Daniel R Zerbino; Ewan Birney
Journal:  Genome Res       Date:  2008-03-18       Impact factor: 9.043

2.  Toward an online repository of Standard Operating Procedures (SOPs) for (meta)genomic annotation.

Authors:  Samuel V Angiuoli; Aaron Gussman; William Klimke; Guy Cochrane; Dawn Field; George Garrity; Chinnappa D Kodira; Nikos Kyrpides; Ramana Madupu; Victor Markowitz; Tatiana Tatusova; Nick Thomson; Owen White
Journal:  OMICS       Date:  2008-06

3.  Genetic instability and strain degeneration in Streptomyces rimosus.

Authors:  B Gravius; T Bezmalinović; D Hranueli; J Cullum
Journal:  Appl Environ Microbiol       Date:  1993-07       Impact factor: 4.792

Review 4.  Genetics of Streptomyces rimosus, the oxytetracycline producer.

Authors:  Hrvoje Petković; John Cullum; Daslav Hranueli; Iain S Hunter; Natasa Perić-Concha; Jasenka Pigac; Arinthip Thamchaipenet; Dusica Vujaklija; Paul F Long
Journal:  Microbiol Mol Biol Rev       Date:  2006-09       Impact factor: 11.056

5.  Draft Genome Sequence of the Oxytetracycline-Producing Bacterium Streptomyces rimosus ATCC 10970.

Authors:  Florence E Pethick; Alison C Macfadyen; Zhenyu Tang; Vartul Sangal; Tze-Tze Liu; Ju Chu; Gregor Kosec; Hrvoje Petkovic; Meijin Guo; Ralph Kirby; Paul A Hoskisson; Paul R Herron; Iain S Hunter
Journal:  Genome Announc       Date:  2013-03-07
  5 in total
  2 in total

1.  Reference-Grade Genome and Large Linear Plasmid of Streptomyces rimosus: Pushing the Limits of Nanopore Sequencing.

Authors:  Lucija Slemc; Jernej Jakše; Alessandro Filisetti; Damir Baranasic; Antonio Rodríguez-García; Francesco Del Carratore; Stefano Maria Marino; Jurica Zucko; Antonio Starcevic; Martin Šala; Mercedes Pérez-Bonilla; Marina Sánchez-Hidalgo; Ignacio González; Fernando Reyes; Olga Genilloud; Vicki Springthorpe; Dušan Goranovič; Gregor Kosec; Gavin H Thomas; Davide De Lucrezia; Hrvoje Petković; Miha Tome
Journal:  Microbiol Spectr       Date:  2022-04-04

2.  Metabolic engineering of Escherichia coli for de novo production of 3-phenylpropanol via retrobiosynthesis approach.

Authors:  Zhenning Liu; Xue Zhang; Dengwei Lei; Bin Qiao; Guang-Rong Zhao
Journal:  Microb Cell Fact       Date:  2021-06-27       Impact factor: 5.328

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.